InMed Pharmaceuticals Regains Nasdaq Compliance, Averting Delisting Threat
Summary
InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, receiving notice on June 3, 2026, that its stock traded above $1.00 for 10 consecutive business days. This follows a March 27, 2026, notification of non-compliance and a May 6, 2026, 10-Q filing that cited Nasdaq delisting risks. The stock's recovery above $1.00 coincided with the May 19, 2026, announcement of an all-stock merger with Mentari Therapeutics. Resolving this compliance issue removes an immediate delisting threat, which is a positive for investor confidence and liquidity, especially given the company's ongoing financial challenges and recent merger activity.
At the time of this announcement, INM was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.58 to $5.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.